Fact-checked by Grok 2 weeks ago

Staphylococcus pseudintermedius

Staphylococcus pseudintermedius is a Gram-positive, coagulase-positive belonging to the Staphylococcus intermedius group (SIG), formally recognized as a distinct species in after being previously misclassified as S. intermedius. It primarily colonizes the skin, nasal cavities, and mucous membranes of and , with carriage rates in healthy ranging from 37% to 92%, often acquired vertically from mothers at birth. As an opportunistic pathogen, it is a leading cause of infections in companion animals, including , , surgical site infections, urinary tract infections, and more severe conditions like and in . In and other species such as , foxes, and , it is less common but has been isolated from similar sites, indicating a broadening host range beyond primary reservoirs. The bacterium's pathogenicity is driven by virulence factors analogous to those in Staphylococcus aureus, enabling , immune evasion, and tissue damage. In humans, S. pseudintermedius exhibits zoonotic potential, with at least 69 documented cases of and reported globally from 2006 to 2022, and additional cases identified since, predominantly skin and soft tissue infections (SSTIs) but also rare invasive cases like bacteremia and , almost exclusively linked to close with infected dogs or . Transmission occurs through direct or fomites, with household ownership identified as a key . Antibiotic resistance, particularly methicillin resistance mediated by the mecA gene (resulting in MRSP), poses significant therapeutic challenges, with prevalence exceeding 60% in some regions like , , and , and multidrug resistance affecting up to 63% of clinical isolates in studies from . Resistance to critical agents like , , and is rare but has been reported in some isolates, necessitating ongoing . The emergence of novel staphylococcal cassette chromosome mec (SCCmec) elements in S. pseudintermedius highlights its role as a reservoir for resistance genes with implications for both veterinary and human medicine under the framework. Improved diagnostics, such as MALDI-TOF , have enhanced identification and , underscoring the need for integrated approaches to mitigate its spread across species.

Taxonomy and Morphology

Classification History

Staphylococcus pseudintermedius was first described as a distinct in 2005, when Devriese et al. proposed its as a novel coagulase-positive staphylococcus within the Staphylococcus intermedius group (SIG), comprising S. intermedius, S. pseudintermedius, and S. delphini. This separation was based on phenotypic differences, including negative clumping factor activity, variable DNase reactions, and lack of acidification compared to S. intermedius and S. delphini, as well as genetic analyses showing 16S rRNA sequence similarities exceeding 99% but DNA-DNA hybridization values below 70%, confirming distinct species status. The type strain, LMG 22219T, was isolated from , with additional strains from sources like , highlighting its primary association with companion animals. Subsequent studies refined identification through species-specific genetic markers, particularly differences in the thermonuclease (nuc) gene sequences. Sasaki et al. (2007) developed multiplex assays targeting unique nuc regions, enabling differentiation of SIG species where phenotypic methods often failed, as many veterinary isolates previously misidentified as S. intermedius were reclassified as S. pseudintermedius. Combined with 16S rRNA analysis, these markers established S. pseudintermedius as the predominant canine-adapted member of the SIG, distinct from the pig-associated S. delphini and the less host-specific S. intermedius. Phylogenetically, S. pseudintermedius occupies a position among coagulase-positive staphylococci, forming a tight cluster with the SIG separate from the S. aureus clade, yet sharing biochemical traits like production that reflect for host adaptation. Its close relation to S. aureus is evident in genomic features such as similar accessory gene regulators, but core genome analyses underscore host specificity, with most isolates from dogs exhibiting adaptations like enhanced adhesion to canine corneocytes. Recent whole-genome sequencing efforts up to 2025 have further elucidated its , revealing a clonal population structure dominated by complexes such as CC71, an lineage often linked to and global spread in veterinary settings. Pan-genomic studies on and North American populations have identified over 13 clonal complexes, including emerging ones like ST496, refining the understanding of intraspecies diversity and evolutionary dynamics without altering its delineation.

Cellular and Colonial Characteristics

Staphylococcus pseudintermedius is a Gram-positive bacterium characterized by spherical cocci measuring approximately 0.5–1.5 μm in diameter, typically arranged in grape-like clusters. These cells are non-motile and non-spore-forming, consistent with other members of the Staphylococcus genus. As a facultative anaerobe, it thrives in both aerobic and anaerobic conditions. On blood agar, S. pseudintermedius forms small, round, creamy-white to greyish-white, opaque colonies, 1–2 mm in diameter, with smooth margins and complete β-hemolysis, often appearing as a double zone after incubation at 37°C for 24–48 hours. The bacterium is catalase-positive, producing bubbles upon exposure to , but oxidase-negative, failing to produce a color change with . It demonstrates growth on selective such as , tolerating the high salt concentration, though mannitol fermentation may be weak or delayed.

Habitat and Epidemiology

Primary Reservoirs and Carriage

Staphylococcus pseudintermedius primarily resides as a commensal bacterium in , where it colonizes the and mucous membranes of healthy individuals. Carriage rates in range from 37% to 92%, with up to 90% reported in some studies for nasal, oral, and sites. This high prevalence underscores as the main , where the bacterium persists asymptomatically without causing in most cases. In addition to dogs, S. pseudintermedius has been isolated from other animals, though less frequently. Cats show lower carriage rates, around 2-12%, while and such as foxes also serve as hosts. The bacterium appears opportunistically in like pigs and in birds, including pigeons, but these are not primary reservoirs. Colonization in dogs often occurs persistently in specific sites, including the perianal and inguinal regions, as well as perinasal and perioral areas, with and being the most common at 65-66% carriage. Transmission happens primarily through direct between animals or via fomites such as shared . carriage prevalence in pet dogs is estimated at 37-92%, with higher rates observed in multi-pet households due to increased contact opportunities.

Prevalence in Companion Animals

Staphylococcus pseudintermedius is recognized as the predominant bacterial in various infections affecting companion animals, particularly , where it is the most frequently isolated species in cases of , , and surgical site infections. In canine , it accounts for approximately 42% of bacterial isolates, while in , isolation rates range from 20% to 94% among staphylococcal cases. For surgical site infections, it represents up to 90% of staphylococcal isolates recovered from affected . Several risk factors contribute to the development of S. pseudintermedius infections in dogs, including underlying conditions such as allergies (e.g., ), immunosuppression, and breed predispositions. Breeds like bulldogs, pugs, boxers, and shar peis are particularly susceptible due to their conformations and predisposition to hypersensitivities, which compromise the skin barrier and facilitate bacterial overgrowth. Endocrinopathies, such as , and ectoparasite infestations further exacerbate vulnerability by altering skin integrity. Prevalence data indicate that S. pseudintermedius is implicated in up to 90% of superficial bacterial cases in , highlighting its role as a primary opportunistic in recurrent conditions. In , infections are less common but emerging, particularly in wound sites, with isolation rates around 6% in wound samples and MRSP accounting for up to 24.7% of such isolates. carriage on the and mucosae often serves as a precursor to these opportunistic infections in both species. Additionally, multi-drug resistant strains, including methicillin-resistant S. pseudintermedius (MRSP), have shown a marked increase since the , complicating in veterinary across regions.

Global Distribution Patterns

Staphylococcus pseudintermedius is widely distributed in developed regions with high rates of companion animal ownership, particularly in and , where isolation rates from veterinary clinical samples typically range from 10% to 30%. In (Germany), a large-scale of 175,171 veterinary samples reported a 25.6% isolation rate for S. pseudintermedius, with 35% in specimens. Similarly, in , proportions of methicillin-resistant S. pseudintermedius (MRSP) in clinical isolates often exceed 10% outside low-prevalence areas like , reflecting its role as a common opportunistic in pets. Reports of S. pseudintermedius have increased in Asia and Australia since 2015, attributed to the expansion of the international pet trade facilitating bacterial dissemination. In Asia, MRSP lineages such as clonal complex (CC) 45 predominate, with isolation frequencies reaching up to 67% in certain veterinary settings in countries like Japan. Australia has documented diverse MRSP sequence types, including ST71 and novel variants, in canine samples, signaling emerging clonal diversity linked to global pet movements. In contrast, occurrences in Africa remain rare, likely due to underreporting stemming from limited diagnostic capabilities and surveillance in veterinary practices. Veterinary laboratory surveillance data highlight the clonal spread of MRSP lineages across continents, with ST71 (part of CC71) originating in and disseminating to and beyond through infected animals. Multilocus sequence typing (MLST) analyses from international multicentre studies confirm this intercontinental transmission, with CC71 accounting for over 50% of European MRSP isolates. Recent genomic surveillance efforts as of 2025, including phylogenomic analyses of thousands of global isolates, have identified multidrug-resistant lineages like CC551 with potential for dissemination via international pet movements, underscoring the need for enhanced border controls on animal movements. As of 2025, studies continue to report increasing MRSP prevalence in and .

Pathogenesis

Adhesion and Invasion Mechanisms

Staphylococcus pseudintermedius initiates through specialized adhesins that mediate attachment to host components and plasma proteins. The clumping factor A (ClfA), a sortase-anchored surface protein, binds specifically to the α-chain of fibrinogen, facilitating bacterial clumping and to fibrinogen-coated surfaces in wounds or mucosal sites. Similarly, the fibronectin-binding proteins SpsD and SpsL, also anchored via the LPXTG by sortase enzymes, interact with in the , promoting stable colonization of epithelial and damaged tissues. These adhesins exhibit growth phase-dependent expression, with SpsD predominant in early exponential phases and SpsL active across multiple stages, enhancing versatility in host attachment. Biofilm formation further supports persistent adhesion and evasion of clearance mechanisms. The polysaccharide intercellular adhesin (PIA), produced via the icaADBC operon, forms a protective matrix that interconnects bacterial cells, enabling the development of robust, multilayered biofilms on skin and implant surfaces. This PIA-dependent process is prevalent in clinical isolates, correlating with enhanced resistance to shear forces and antimicrobial penetration during chronic canine pyoderma. Invasion into host cells is driven by sortase-anchored surface proteins, particularly SpsD and SpsL, which not only bind but also induce uptake into epithelial cells. By engaging α5β1 on host cells, these proteins activate signaling cascades that internalize , allowing dissemination from initial adhesion sites into deeper tissues and contributing to the severity of wound infections. Mutants lacking these proteins show significantly reduced efficiency, underscoring their essential role. Adaptation to the canine host is exemplified by the iron-regulated surface determinant (Isd) system, which facilitates heme acquisition tailored to canine physiology. The IsdB receptor demonstrates species-specific binding to canine hemoglobin, enabling efficient heme extraction under iron-limiting conditions prevalent in infected tissues. This evolutionary divergence from human-specific IsdB in Staphylococcus aureus enhances S. pseudintermedius survival and virulence in dogs, promoting tropism to this primary reservoir.

Immune Evasion Strategies

Staphylococcus pseudintermedius employs (), a key surface-anchored protein, to evade host immune responses by binding the Fc region of () antibodies. This interaction prevents opsonization, thereby inhibiting by neutrophils and macrophages, and also interferes with complement activation, reducing bacterial clearance. Studies have demonstrated that expression in S. pseudintermedius mirrors its function in , where it cross-links molecules to form immune complexes that shield the bacterium from . The production of capsular , often manifesting as an antiphagocytic composed of polysaccharide intercellular adhesin (), further contributes to immune evasion by S. pseudintermedius. This reduces bacterial uptake by neutrophils, embedding cells within biofilms that hinder access to and promote persistence during infections. Slime-producing isolates are more prevalent in diseased companion , underscoring its role in facilitating chronic colonization and resisting innate immunity. Superantigen-like proteins (SSLs) secreted by S. pseudintermedius modulate host responses, diverting immune signaling to favor bacterial survival. These proteins interfere with innate immune pathways, such as those involving Toll-like receptors, leading to dysregulated release that promotes chronic inflammation, particularly in skin infections like . By altering the inflammatory milieu, SSLs enable prolonged bacterial presence without triggering effective adaptive immunity. Recent genomic analyses have highlighted leukocidin genes, such as lukF-I and lukS-I encoding the canine-specific leukotoxin Luk-I, which specifically lyse s in dogs, impairing the primary line of innate defense. This two-component pore-forming toxin targets polymorphonuclear leukocytes, causing rapid and release of contents that may exacerbate damage while clearing key immune effectors. The presence of these genes in clinical isolates from 2024 underscores their contribution to in opportunistic infections.

Toxin Production and Tissue Damage

Staphylococcus pseudintermedius produces several exotoxins that contribute to direct tissue damage during infections, primarily in hosts. Among these, leukocidins such as Luk-I (comprising LukS-I and LukF-I subunits) are bicomponent pore-forming toxins homologous to the Panton-Valentine leukocidin (PVL) of S. aureus. These toxins target and lyse neutrophils and other leukocytes by binding to the CXCR2 receptor, leading to pore formation in cell membranes and subsequent cell death, which promotes formation and necrotizing lesions in and soft tissues. Luk-I is encoded on a degenerate and is present in nearly all clinical isolates examined. Phenol-soluble modulins (PSMs), including δ-toxin and the canine-specific PSMε, are amphipathic α-helical peptides that disrupt host cell membranes, lyse neutrophils, and promote and formation. These toxins enhance bacterial dissemination and contribute to the severity of and infections in dogs by damaging epithelial barriers and evading innate immunity. Enterotoxins and exfoliative toxins are less prevalent but play roles in severe dermatological conditions. Enterotoxin genes like sea (17% prevalence) and sec (57% in clinical strains) encode superantigen-like proteins, such as SEA homologs, which can induce and disruption, though their direct link to remains limited. Exfoliative toxins, including SIET (detected in nearly all isolates studied), EXI (23.3% in pyoderma cases), and ExpA/ExpB, cleave desmoglein-1 in the , causing intraepidermal splitting, , crusting, and severe akin to scalded . These toxins exacerbate barrier breakdown, facilitating deeper invasion and chronic infections. In addition to exotoxins, S. pseudintermedius secretes enzymes that degrade host tissues to enhance pathogenicity. Lipases hydrolyze lipids in and subcutaneous layers, enabling bacterial nutrient acquisition and penetration into deeper tissues, which contributes to the spread of infections like and abscesses. Hyaluronidases break down in extracellular matrices, promoting bacterial dissemination and tissue liquefaction in infected sites. These enzymes are consistently produced across strains but do not vary significantly between healthy carriers and pathogenic isolates. Toxin and enzyme profiles exhibit strain variability, particularly among clonal complexes (CCs), with higher expression in pathogenic lineages. For instance, CC71 (common in methicillin-resistant strains) often harbors multiple enterotoxin and exfoliative genes, correlating with increased in severe s, while CC84 shows lower diversity. This variability influences disease severity, as isolates from deep express elevated levels of leukocidins and exfoliative toxins compared to superficial colonizers. These cytotoxins also indirectly modulate immunity by depleting leukocyte populations at sites.

Diagnosis

Specimen Collection and Initial Examination

Specimen collection for Staphylococcus pseudintermedius primarily involves obtaining swabs from infected sites in companion animals, particularly , where it commonly causes and other skin infections. Preferred specimens include swabs from intact pustules, epidermal collarettes, crust edges, ear canals, or open wounds, as these sites yield high bacterial loads while minimizing contamination from commensal flora. For deep s involving nodules or furuncles, or small punch biopsies (3-4 mm) may be used to access subcutaneous material. Collection must be performed aseptically to prevent extraneous : clip surrounding with sterile (avoiding clippers to reduce skin ), avoid surface disinfection of lesions, and use sterile needles or to pustules or lift crusts before swabbing with a sterile cotton-tipped swab. Swabs should be immediately placed in a suitable transport medium, such as Amies or Carry-Blair, to inhibit overgrowth by non-target and maintain viability. Specimens are best stored at 4°C and processed within 24 hours to preserve bacterial integrity, though some media like ESwab support up to 48 hours at ambient temperature. Initial examination typically begins with cytological evaluation via direct of impression smears or tape preparations from surfaces. Gram staining reveals characteristic Gram-positive cocci arranged in clusters, often phagocytosed within degenerate neutrophils, indicating active . Modified Wright's or staining highlights inflammatory cells, such as neutrophils and macrophages, alongside extracellular and intracellular cocci, providing rapid assessment of bacterial morphology and host response. Direct microscopic screening estimates bacterial load but has limited sensitivity in low-density infections, where may not be visible despite clinical signs, necessitating confirmatory in such cases. Cytology alone cannot speciate S. pseudintermedius from other coagulase-positive staphylococci, underscoring the need for follow-up microbiological testing when infection is suspected.

Culture-Based Identification

Staphylococcus pseudintermedius is typically isolated from clinical specimens using non-selective or semi-selective media such as 5% sheep blood agar or Columbia colistin-nalidixic acid (CNA) agar, which inhibit the growth of many Gram-negative bacteria while supporting staphylococcal proliferation. Primary plating involves streaking the specimen onto these media and incubating aerobically at 37°C for 24–48 hours, allowing for the development of characteristic colonies. On blood agar, colonies appear as small (1–3 mm), round, smooth, opaque, and creamy gray to white, often exhibiting complete (beta) hemolysis, which contributes to presumptive identification as a potentially pathogenic coagulase-positive staphylococcus. Presumptive identification relies on standard microbiological tests to confirm staphylococcal characteristics and activity. The organism is Gram-positive, catalase-positive, and forms cocci in clusters, but key tests include the assays: a positive test using (clotting within 4–24 hours) is reliable, while the slide test (bound detection via clumping) may yield weak or negative results due to lower clumping factor expression. The beta-hemolysis pattern observed on blood agar further supports this presumptive classification, distinguishing it from non-hemolytic staphylococci. To differentiate S. pseudintermedius from the closely related , additional biochemical tests are employed. The DNase test, performed on DNase agar with toluidine blue at 37°C, yields positive results for S. pseudintermedius, producing a clear zone around colonies after flooding with HCl, similar to S. aureus but confirming extracellular production. Novobiocin susceptibility testing, using disks on Mueller-Hinton agar, shows sensitivity (inhibition zones ≥16 mm at 5 μg concentration), which aligns with the profile of coagulase-positive staphylococci but helps rule out novobiocin-resistant species like certain coagulase-negative staphylococci. These tests, while useful, require careful interpretation as phenotypic overlap with S. aureus can occur. Culture-based methods have limitations, including the potential overgrowth of contaminating staphylococci or other on less selective , which may obscure S. pseudintermedius colonies and necessitate subculturing for isolation of pure colonies. Additionally, variable expression of certain traits, such as reactivity, can lead to initial misidentification without confirmatory steps.

Molecular and Biochemical Confirmation

Following initial isolation through culture-based methods, definitive identification of Staphylococcus pseudintermedius relies on molecular and biochemical techniques that provide species-level precision, distinguishing it from closely related coagulase-positive staphylococci such as S. aureus and other members of the S. intermedius group (SIG). (PCR) assays targeting species-specific s are widely employed for rapid confirmation. A key target is the nuc , which encodes a thermostable unique to S. pseudintermedius; primers amplify a 99-bp fragment in real-time PCR formats using SYBR Green detection, achieving high specificity when validated against reference strains. Alternative molecular approaches may target the phosphotransacetylase (pta) , which exhibits sequence divergence facilitating species discrimination via PCR-restriction fragment length polymorphism (RFLP) analysis, though nuc-based methods remain more routinely adopted due to their simplicity and established protocols. Biochemical confirmation utilizes commercial identification systems that assess enzymatic profiles and metabolic reactions. The API Staph system () identifies S. pseudintermedius with 83-98% accuracy based on a 20-test strip, typically yielding a profile positive for , , (C4), and esterase-lipase (C8), but negative for , β-, and Voges-Proskauer reaction; these patterns differentiate it from S. aureus (urease-negative but often β-glucuronidase-positive) and other SIG members. Similarly, the VITEK 2 system () employs automated card-based assays for Gram-positive cocci, confirming S. pseudintermedius through comparable activities and susceptibility patterns, with overall agreement exceeding 90% when cross-validated against . These panels are particularly valuable in veterinary diagnostic labs for processing isolates from canine pyoderma or , where phenotypic ambiguity is common. Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) offers a high-throughput alternative by generating species-specific spectral profiles from ribosomal proteins. Systems like VITEK MS or MALDI Biotyper can identify S. pseudintermedius, often as part of the S. intermedius group (SIG), from S. aureus, with log(score) values >2.0 indicating confident identification at the group level; database limitations may group it with S. intermedius, requiring molecular confirmation for species-level separation. This method's speed (minutes per sample) and low cost make it ideal for routine confirmation, outperforming traditional biochemical tests in accuracy for veterinary samples. Recent advances as of 2025 emphasize whole-genome sequencing (WGS) integrated with multi-locus sequence typing (MLST) for not only species confirmation but also clonal tracking. WGS assembles full genomes to verify core SIG markers while applying MLST schemes targeting seven housekeeping genes (e.g., abcZ, adk), identifying prevalent clones like ST71 (dominant in ) and ST68 (dominant in )—methicillin-resistant lineages associated with recurrent infections in companion animals. This approach, enabled by platforms like Illumina or Oxford Nanopore, supports epidemiological surveillance and outperforms single-gene in resolving outbreak strains, though its adoption remains limited to reference labs due to cost.

Antimicrobial Resistance

Mechanisms of Resistance

Staphylococcus pseudintermedius exhibits through multiple genetic and biochemical mechanisms that enable survival in the presence of antibiotics. One primary pathway involves resistance, mediated by the gene, which encodes the penicillin-binding protein 2a (PBP2a). This altered protein has a low affinity for , allowing continued synthesis despite exposure to drugs like and oxacillin. The gene is typically integrated into the staphylococcal cassette chromosome mec (SCCmec), a mobile genetic element that facilitates its dissemination among bacterial populations. Multidrug efflux pumps represent another key resistance strategy in S. pseudintermedius, actively expelling from the bacterial cell to reduce intracellular concentrations. NorA-like transporters, belonging to the major facilitator superfamily, are particularly implicated in to fluoroquinolones such as and by pumping these hydrophilic compounds out of the cell. Similarly, efflux systems like Tet(K) and Tet(L) contribute to by exporting drugs like , thereby diminishing their bacteriostatic effects. These pumps are often chromosomally encoded but can be overexpressed under selective pressure from subinhibitory concentrations. Biofilm formation further enhances in S. pseudintermedius, particularly in chronic infections where bacterial communities adhere to host tissues or medical devices. Within , extracellular polymeric substances create a physical barrier that limits penetration, while slow-growing persister cells exhibit intrinsic tolerance to agents. This matrix-associated can increase minimum inhibitory concentrations by factors of 10 to 1000 compared to planktonic cells, complicating eradication in conditions like canine pyoderma or . Diagnostic tests for , such as , may briefly reference effects but primarily assess planktonic growth. Horizontal gene transfer amplifies resistance dissemination in S. pseudintermedius through like plasmids and transposons. Plasmids often carry genes for efflux pumps or aminoglycoside-modifying enzymes, enabling conjugative transfer between staphylococcal species during co-infections. Transposons, such as Tn916-like elements, mobilize resistance determinants via events, integrating into the chromosome or other plasmids. These mechanisms promote interspecies exchange, including with , heightening the risk of multidrug-resistant strains emerging in veterinary and human settings.

Methicillin-Resistant Strains (MRSP)

Methicillin-resistant Staphylococcus pseudintermedius (MRSP) emerged as a significant veterinary around 2006, with the first reports documented in from clinical cases in dogs. Since then, MRSP has become globally disseminated, particularly in companion animal populations, where it accounts for 10–30% of S. pseudintermedius isolates in many veterinary clinical settings. This resistance is primarily mediated by the acquisition of the gene, which encodes a penicillin-binding protein conferring resistance to and other β-lactam antibiotics. The epidemiology of MRSP is dominated by specific clonal lineages that have facilitated its rapid spread. In Europe, the sequence type ST71 clone, often associated with SCCmec types II–III, was predominant until around 2015, while in North America, the ST68 clone carrying SCCmec type V remains most common; both lineages exhibit multidrug resistance profiles beyond β-lactams. As of 2025, emerging clones such as ST551 have become dominant in parts of Europe, replacing ST71, with additional lineages like ST258 and ST726 reported in Europe and Asia, contributing to ongoing outbreaks and intercontinental spread through pet travel and trade. These clones have contributed to outbreaks in veterinary hospitals and have been detected across continents through pet travel and trade. Key risk factors for MRSP colonization and infection in pets include prior exposure to antibiotics, particularly β-lactams and fluoroquinolones, which select for resistant strains in populations. Hospital-acquired transmission is also prominent, with MRSP spreading within veterinary clinics via contaminated environments, equipment, and direct animal contact, leading to nosocomial infections in affected facilities.

Treatment Implications and Alternatives

Treatment of methicillin-susceptible Staphylococcus pseudintermedius (MSSP) infections primarily relies on , with cephalexin (22–30 mg/kg PO q12h) or amoxicillin-clavulanate (12.5–25 mg/kg PO q12h) as first-line options for , administered for 3–6 weeks until clinical resolution plus one week. These agents are selected due to their efficacy against the majority of MSSP isolates and favorable safety profiles in . For methicillin-resistant S. pseudintermedius (MRSP), beta-lactams are ineffective owing to mecA-mediated resistance, necessitating susceptibility-guided therapy with alternatives such as (5–10 mg/kg PO q12h) or potentiated sulfonamides like trimethoprim-sulfadiazine (15–30 mg/kg PO q12h), provided susceptibility is confirmed. Topical therapies, including 2–4% washes (applied every 1–3 days) and ointment for localized lesions, form the cornerstone of MRSP management to minimize systemic and reduce bacterial carriage. Adjunctive measures enhance outcomes across both MSSP and MRSP cases; topical antiseptics like are recommended universally to decrease skin colonization and shorten systemic treatment duration. For deep or abscesses, surgical is advised to remove necrotic tissue and facilitate healing. The International Society for Companion Animal Infectious Diseases (ISCAID) guidelines, updated in 2025, emphasize by prioritizing topical therapies, mandating culture and susceptibility testing for recurrent or severe infections, and limiting systemic use to confirmed cases to mitigate resistance development.

Zoonotic Potential

Transmission Routes to Humans

_Staphylococcus pseudintermedius, primarily a of companion animals such as , transmits to s mainly through zoonotic pathways involving close animal . The bacterium the skin, mucosae, and of at rates up to 90%, establishing them as the principal reservoir for human exposure. Direct occurs predominantly via physical with infected or colonized pets, particularly through handling of wounds, exposure to during bites or licks, and skin-to-skin interactions. This route poses the highest risk to veterinarians, dog owners, and individuals with frequent pet handling, as evidenced by colonization rates of 4.5–5.6% among dog guardians and veterinary staff. Indirect transmission is less common but facilitated by contaminated environments and fomites, such as grooming tools, surfaces, or household items shared with pets. Studies have detected S. pseudintermedius on veterinary clinic equipment and in animal housing areas, enabling transfer to humans via touch. Airborne or foodborne routes are rarely documented and considered negligible, with no substantial evidence supporting their role in human acquisition. Molecular typing methods, including (PFGE) and (MLST), have confirmed transmission by identifying identical strains in dog-human pairs, such as ST71 clones matching between pets and their owners. Human infections with S. pseudintermedius were first documented in 2006, with subsequent reports indicating low overall incidence but a potential increase linked to rising ownership and closer human-animal interactions. A case series of 24 infections highlighted pet exposure in 95.4% of cases, underscoring the zoonotic link without widespread community spread. remains uncommon, occurring primarily in households or veterinary settings where direct or fomite-mediated contact predominates.

Clinical Manifestations in Humans

Staphylococcus pseudintermedius primarily causes skin and soft tissue (SSTIs) in humans, such as abscesses and , particularly among individuals with close contact to or those who are immunocompromised. These often arise from wounds, including bites, and are typically mild to moderate in severity, allowing management on an outpatient basis with oral antibiotics. In a series of 24 human cases, 75% involved SSTIs, with the majority resolving without hospitalization. Systemic infections by S. pseudintermedius are rare but can occur in vulnerable populations, such as the elderly, diabetics, or those with underlying malignancies, manifesting as bacteremia, surgical site infections, or . For instance, bacteremia has been documented in immunocompromised patients with indwelling devices, sometimes leading to or requiring inpatient care. cases, including externa, have been reported in elderly individuals with pet exposure. Unlike the commonly seen in canine hosts, human infections lack an equivalent primary and show a stronger association with traumatic wounds. As of 2023, at least 87 human cases have been documented in the literature, often initially misidentified as Staphylococcus aureus due to biochemical similarities, which can delay appropriate diagnosis. A 2023 review (as of December 2022) identified 97 publications on human infections since the first report in 2006, with most cases mild but highlighting the pathogen's potential for severity in at-risk groups. Cases continue to be reported into 2025, including rare instances of severe infections like aortitis. Transmission from companion animals, especially dogs, is a common predisposing factor.

Risk Factors and Prevention Strategies

Individuals at higher risk for zoonotic of Staphylococcus pseudintermedius include those with frequent close contact to infected or colonized companion animals, particularly . Veterinarians and veterinary staff face elevated occupational exposure , with studies showing carriage rates of methicillin-resistant S. pseudintermedius (MRSP) up to 4% among small animal dermatologists due to direct handling of infected animals. Immunocompromised individuals, such as those with weakened immune systems from underlying conditions or treatments, are particularly vulnerable to opportunistic from the bacterium. Elderly persons with pet contact also exhibit increased susceptibility, as evidenced by case reports of severe like bacteremia in older adults cohabitating with carrier . Children, especially young ones engaging in close play with pets, may face heightened through direct contact, necessitating targeted education for households. Conditions compromising skin integrity, such as , further amplify susceptibility by facilitating bacterial colonization and entry in humans with frequent animal exposure. Prevention strategies emphasize basic infection control measures to interrupt transmission from pets to humans. Rigorous hand hygiene, including thorough washing with soap and water or use of alcohol-based sanitizers after pet handling, is the cornerstone of personal protection and has been shown to significantly reduce carriage risks in high-exposure settings. In households with infected pets, prompt wound care—such as cleaning and covering any breaks in the skin—is essential to prevent bacterial ingress, particularly for at-risk family members. For pets identified as carriers, decolonization protocols involving topical antiseptics like baths can effectively reduce bacterial loads on the skin and mucous membranes, thereby lowering household transmission potential. Public health efforts focus on and to mitigate broader zoonotic threats from S. pseudintermedius, especially MRSP strains. Routine monitoring of bacterial on surfaces and in air within veterinary clinics helps identify and contain outbreaks, with environmental sampling revealing persistent risks in high-traffic areas. Educational initiatives targeting MRSP risks have been promoted since , when updated susceptibility testing guidelines were introduced to enhance diagnostic accuracy and awareness among veterinary professionals. As of 2025, the and aligned frameworks advocate approaches, integrating human, animal, and environmental health in pet-dense urban areas to address spread from companion animals.

References

  1. [1]
    Not just in man's best friend: A review of Staphylococcus ...
    Staphylococcus pseudintermedius is a common commensal and pathogen in dogs. Although adapted to dogs it has been isolated from a wide range of host species.
  2. [2]
    Understanding the Virulence of Staphylococcus pseudintermedius
    Staphylococcus pseudintermedius is a skin and mucous commensal bacterium in dogs, with carriage reaching more than 80% in some populations of healthy dogs ( ...
  3. [3]
    Exploring Staphylococcus Pseudintermedius: an Emerging Zoonotic ...
    Staphylococcus pseudintermedius is a common colonizer of companion animals and particularly dogs, and is most frequently associated with skin and soft tissue ...
  4. [4]
    Methicillin-resistant Staphylococcus pseudintermedius - PubMed
    Aug 21, 2024 · Staphylococcus pseudintermedius is a major opportunistic bacterial pathogen that belongs to the skin and mucosal microbiota of the dog.
  5. [5]
  6. [6]
    Staphylococcus pseudintermedius - VetBact
    Mar 8, 2023 · Small round, greyish white, opaque colonies (1-2 mm in diameter) with smoth margin. Does often give a double hemolysis zone on blood agar.
  7. [7]
    The Genera Staphylococcus and Macrococcus - PMC
    Members of the genus Staphylococcus are Gram-positive cocci (0.5–1.5 µm in diameter) that occur singly, in pairs, tetrads, short chains (three or four cells), ...Missing: pseudintermedius | Show results with:pseudintermedius
  8. [8]
    Human Colonization and Infection by Staphylococcus ... - MDPI
    Feb 25, 2023 · S. pseudintermedius is a known resident of the skin and mucous membranes and a constituent of the normal microbiota of dogs.<|separator|>
  9. [9]
    Staphylococcus intermedius Group—Look What the Dog Dragged In
    Jan 24, 2018 · Like S. aureus, SIG isolates may grow on mannitol salt agar, which is often used in S. aureus colonization screening cultures, and many will ...
  10. [10]
    First Case of Staphylococcus pseudintermedius Infection in a Human
    Staphylococcus pseudintermedius has been recently described as a new coagulase-positive species of animals (2). This case report describes, to our knowledge, ...Missing: original | Show results with:original
  11. [11]
    Human Colonization and Infection by Staphylococcus ...
    Feb 25, 2023 · S. pseudintermedius grows as small blue colonies on CHROMagar Staph aureusTM and as small, creamy grey-to-white, round 1–3 mm colonies with β- ...
  12. [12]
    Staphylococcus Intermedius Infections: Case Report and Literature ...
    More recently, the discovery of Staphylococcus pseudintermedius in 2005 has led to the reclassification of isolates formerly identified as S. intermedius based ...
  13. [13]
    Diverse Populations of Staphylococcus pseudintermedius Colonize ...
    Feb 14, 2023 · pseudintermedius isolates from different skin sites in 9 healthy dogs. ... sites: perinasal, perioral, inguinal, and perianal. These four ...
  14. [14]
    Staphylococcus pseudintermedius colonization patterns and strain ...
    Dec 7, 2012 · The most frequent carriage sites were the perineum (66%) and the mouth (65%) followed by the nose (27%) and the groin (23%).Missing: perianal | Show results with:perianal
  15. [15]
    Canine Pyoderma and Otitis Externa: A Retrospective Analysis of ...
    Staphylococcus spp., particularly S. pseudintermedius, were identified as the most prevalent bacterial genus isolated from both canine pyoderma (42.4%) and ...
  16. [16]
    antimicrobial‐resistant Staphylococcus pseudintermedius in dogs ...
    Feb 1, 2022 · An older study found a significantly higher proportion of nasal or oral carriage of S. intermedius (likely S. pseudintermedius) in owners of ...
  17. [17]
    Investigation of antimicrobial susceptibility and genetic diversity ...
    Nov 18, 2023 · We evaluated S. pseudintermedius distribution among infected and colonized dogs. We also analyzed the antimicrobial resistance profile of the studied isolates.Mlst And Sccmec Typing · Discussion · Pcr Detection Of The Nuc And...
  18. [18]
    Dermatological Problems of Brachycephalic Dogs - MDPI
    The British Bulldog, Pug, Boxer, Shar Pei, and Bullmastiff are predisposed to superficial bacterial folliculitis, which is usually associated with ...
  19. [19]
    Comparative Analysis of Methicillin-Resistant Staphylococcus ...
    Jul 17, 2024 · In cats, S. pseudintermedius displayed elevated resistance rates, particularly in samples from wounds (24.7%) and urogenital tract infections ( ...
  20. [20]
    [PDF] Staphylococcus pseudintermedius, both commensal and pathogen
    The anal, perineal and nasal locations appear to be the main S. pseudintermedius colonization sites, from which bacteria are transmitted to other body sites, ...Missing: inguinal | Show results with:inguinal
  21. [21]
    Comparative Analysis of Methicillin-Resistant Staphylococcus ...
    Jul 17, 2024 · pseudintermedius in 44,880 samples, yielding a 25.6% isolation rate. S. pseudintermedius was more prevalent in dogs (35.0%) than cats (3.6%).
  22. [22]
    Systematic Review on Global Epidemiology of Methicillin-Resistant ...
    The population of S. pseudintermedius was highly diverse and included five major MRSP clonal complexes (CCs). CC71, previously described as the epidemic ...
  23. [23]
    Clonal diversity and geographic distribution of methicillin-resistant ...
    Clonal diversity and geographic distribution of methicillin-resistant Staphylococcus pseudintermedius from Australian animals: Discovery of novel sequence types.Missing: Asia | Show results with:Asia
  24. [24]
    Clonal spread of methicillin-resistant Staphylococcus ...
    Mar 25, 2010 · The aim of this study was to determine the phenotypic and genotypic resistance profiles of methicillin-resistant Staphylococcus pseudintermedius (MRSP)
  25. [25]
    Evolving landscape of methicillin-resistant Staphylococcus ...
    Sep 27, 2025 · This study aims to identify spatiotemporal variations in clonal diversity and antimicrobial resistance of methicillin-resistant ...
  26. [26]
    Global phylogenomic analysis of Staphylococcus pseudintermedius ...
    Mar 5, 2025 · In this study, we compared the genome sequence of 110 UK isolates of S. pseudintermedius with 2166 genomes of S. pseudintermedius populations ...
  27. [27]
    Staphylococcus pseudintermedius expresses surface proteins that ...
    Sep 18, 2009 · This study aimed to determine if S. pseudintermedius expresses surface proteins resembling those from Staphylococcus aureus and to characterise them.
  28. [28]
    Genomic and Surface Proteomic Analysis of the Canine Pathogen ...
    Finally, we identify specific CWA proteins expressed by S. pseudintermedius during canine infection which mediate binding to the ECM proteins fibrinogen, ...
  29. [29]
    Exploring the Biofilm Formation Capacity in S. pseudintermedius ...
    Jun 16, 2022 · All isolates formed biofilm, with S. urealyticus producing the most biofilm biomass and S. pseudintermedius producing the least biomass. There ...
  30. [30]
    Fibronectin Binding Proteins SpsD and SpsL Both Support Invasion ...
    In this study, we investigated the cell wall-anchored fibronectin-binding proteins SpsD and SpsL from the canine commensal and pathogen Staphylococcus ...
  31. [31]
    Molecular Basis for the Evolution of Species-Specific Hemoglobin ...
    During infection, bacteria must steal metals, including iron, from the host tissue. Therefore, pathogenic bacteria have evolved metal acquisition systems to ...
  32. [32]
    Expression and function of protein A in Staphylococcus ... - NIH
    Protein A, a highly potent virulence and immune evasion factor, is produced by many species of staphylococci. Within S. aureus it is a 40–60 kDa cell-wall ...
  33. [33]
    Expression and function of protein A in Staphylococcus ... - PubMed
    aureus protein A's ability to bind the Fc region of immunoglobulins and may serve as a potential virulence factor by evading the host immune system. Keywords: ...
  34. [34]
    Characterization of agr Groups of Staphylococcus pseudintermedius ...
    Mar 27, 2019 · Overall biofilm production, measured by CVA, showed that a majority of isolates (78%; 553/710) produced weak or moderately weak biofilms. There ...
  35. [35]
    Comparative RNA-seq-Based Transcriptome Analysis of the ... - NIH
    Staphylococcus pseudintermedius is often associated with pyoderma, which can turn into a life-threatening disease ... superantigen-like proteins), genes ...
  36. [36]
    Characterization of a leukocidin identified in Staphylococcus ...
    Sep 27, 2018 · Bacterial infections from Staphylococcus pseudintermedius are the most common cause of skin infections (pyoderma) affecting dogs.Missing: 2024 | Show results with:2024
  37. [37]
    Isolation of Staphylococcus pseudintermedius in ... - PubMed Central
    Aug 16, 2024 · This study documents four cases of S. pseudintermedius infection or colonization in patients who had close contact with dogs or cats.
  38. [38]
    Understanding the Virulence of Staphylococcus pseudintermedius
    Jun 28, 2018 · Staphylococcus pseudintermedius is responsible for severe and necrotizing infections in humans and dogs. Contrary to S. aureus, ...
  39. [39]
    From canines to humans: Clinical importance of Staphylococcus pseudintermedius
    ### Summary of Toxin Production in *Staphylococcus pseudintermedius*
  40. [40]
    Full article: Virulence factors in coagulase-positive staphylococci of ...
    Several virulence factors (17 for host immune evasion ... Genomic and surface proteomic analysis of the canine pathogen staphylococcus pseudintermedius reveals ...
  41. [41]
    Staphylococcus pseudintermedius exfoliative toxin EXI ... - PubMed
    Recently, a novel exfoliative toxin gene (exi), whose sequence shares significant homology with previously identified exfoliative toxins, was isolated from ...Missing: enterotoxins | Show results with:enterotoxins
  42. [42]
    The Occurrence and Characteristics of Methicillin-Resistant ...
    Aug 4, 2023 · These factors include various extracellular enzymes such as lipases, proteases, amylases, hyaluronidase, DNases, coagulase, lactamase, ...
  43. [43]
    Canine Bacterial Pyoderma: Indications and Skin Sampling ...
    Staphylococcus pseudintermedius is the most common organism associated with canine pyoderma.
  44. [44]
    Staphylococcus Pseudintermedius - an overview - ScienceDirect.com
    Staphylococcus pseudintermedius is a true canine commensal and is found on the skin or mucosal surfaces of a large percentage of dogs.Missing: seasonal humid climates
  45. [45]
    Staphylococcus pseudintermedius and Staphylococcus schleiferi ...
    Jan 23, 2014 · Sample Collection. Samples were obtained from 66 domestic dogs diagnosed with pyoderma between March, 2010, and February, 2012. All cases ...Missing: specimen | Show results with:specimen<|control11|><|separator|>
  46. [46]
    Chromogenic culture media complements diagnostic cytology in the ...
    Jul 10, 2023 · Staphylococcus pseudintermedius (S. pseudintermedius) causes most pyodermas in dogs (3–5) and S. aureus in cats (6–9). Other less common ...
  47. [47]
    Identification of Staphylococcus pseudintermedius Isolates from ...
    Oct 19, 2021 · Staphylococcus pseudintermedius was defined as a novel coagulase-positive staphylococci species in 2005 (1) and has been established as a common ...Results · Table 2 · Table 3
  48. [48]
    Reclassification of Phenotypically Identified Staphylococcus ...
    Sep 1, 2007 · We analyzed molecular phylogenies and phenotypic characteristics of 117 S. intermedius group (SIG) strains tentatively identified as being S. intermedius.
  49. [49]
    Recent Progress in the Diagnosis of Staphylococcus in Clinical ...
    Dec 9, 2022 · Staphylococcus can grow well on blood agar, brain heart infusion agar, tryptone soy agar, and mannitol salt agar [16]. After 24 h of ...
  50. [50]
    Comparison of Culture-Based Methods for Identification of ...
    Methods that allow culture of Staphylococcus spp. other than S. aureus are critical to assess cocolonization outcomes and the presence of animal-associated ...Fig 1 · Table 1 · Table 2Missing: differentiation | Show results with:differentiation
  51. [51]
  52. [52]
  53. [53]
  54. [54]
    Combining MALDI-TOF and genomics in the study of methicillin ...
    Feb 4, 2019 · Whole genome sequencing identifies New Zealand MRSP diversity and resistance genotypes. MDR variants of S. pseudintermedius, including MDR-MRSP, ...
  55. [55]
    Methicillin resistance in Staphylococcus pseudintermedius encoded ...
    Apr 2, 2024 · Treatment is hampered by antimicrobial resistance including methicillin resistance encoded by mecA within the mobile genetic element SCCmec.
  56. [56]
    Review on methicillin-resistant Staphylococcus pseudintermedius
    Sep 19, 2011 · In Canada, the prevalence of MRSP colonization in healthy cats was 1.2%.57 No MRSP was found among 300 horses in different farms in Slovenia.62 ...
  57. [57]
    Inhibition of Staphylococcus pseudintermedius Efflux Pumps by ...
    One promising approach in treating antibiotic-resistant bacteria is to “break” resistances connected with antibacterial efflux by co-administering efflux pump ...
  58. [58]
    Role and regulation of membrane efflux pumps in Staphylococcus ...
    This study aimed to evaluate the efflux capability of Staphylococcus pseudintermedius clinical isolates, investigate its implications in multidrug resistance,
  59. [59]
    Genomic analysis of the Staphylococcus pseudintermedius ...
    CRISPR tracking reveals global spreading of antimicrobial ... Within-household transmission and bacterial diversity of Staphylococcus pseudintermedius.Missing: intercontinental | Show results with:intercontinental
  60. [60]
    antibiotic-resistant biofilm formation by a human wound-associated ...
    May 21, 2015 · Staphylococcus pseudintermedius is an opportunistic pathogen recognized as the leading cause of skin, ear, and post-operative bacterial ...
  61. [61]
    Virulence Potential of Biofilm-Producing Staphylococcus ... - MDPI
    Sep 30, 2022 · It is a commensal organism that is part of the normal flora of the skin and mucous membranes of dogs, colonizing from 25% up to nearly 70% of ...
  62. [62]
    Antibiotic Resistance Profile and Biofilm Production of ... - NIH
    Jun 20, 2021 · Staphylococcus pseudintermedius is an opportunistic pathogen that causes wound infections, pyoderma, otitis externa, and endometritis in canines ...
  63. [63]
    In Vitro Transduction of Antimicrobial Resistance Genes between ...
    Dec 18, 2020 · Horizontal gene transfer (HGT) of MGEs can occur between individual bacteria by transformation, conjugation, or transduction [11]. In S. aureus, ...
  64. [64]
    Plasmid-Mediated Antimicrobial Resistance in Staphylococci and ...
    Plasmids play a key role in the dissemination of antimicrobial resistance genes within the gene pool to which staphylococci and other Firmicutes have access.
  65. [65]
    Staphylococci on ICE: Overlooked agents of horizontal gene transfer
    Horizontal gene transfer plays a significant role in spreading antimicrobial resistance and virulence genes throughout the genus Staphylococcus, which includes ...
  66. [66]
    Clonal spread of methicillin-resistant Staphylococcus ... - PubMed
    Mar 25, 2010 · Two major clonal MRSP lineages have disseminated in Europe (ST71-J-t02-II-III) and North America (ST68-C-t06-V).
  67. [67]
    Risk factors for antimicrobial resistance among Staphylococcus ...
    Apr 14, 2022 · The use of oral or injectable antimicrobials by the pets during the prior year was the main risk factor of interest. Based on our results, 50% ( ...
  68. [68]
    Large Outbreak Caused by Methicillin Resistant Staphylococcus ...
    The purpose of this study was to describe a nosocomial outbreak caused by methicillin resistant Staphylococcus pseudintermedius (MRSP) ST71 SCCmec II-III in ...
  69. [69]
    Antimicrobial use guidelines for canine pyoderma by the ...
    May 7, 2025 · To provide clinicians with antimicrobial treatment guidelines for staphylococcal pyoderma, including those involving meticillin‐resistant staphylococci.Missing: density | Show results with:density
  70. [70]
  71. [71]
    Antimicrobial agents in small animal dermatology for treating ...
    Because Staphylococcus spp are a normal commensal organism on the skin of dogs, these bacteria can cause infections of the skin or any skin-associated ...
  72. [72]
    Managing MRSA, MRSP, and MRSS dermatologic infections in pets
    Jan 1, 2013 · 11 For superficial pyoderma (whether methicillin susceptible or methicillin resistant), antibiotics are required for at least three weeks (one ...
  73. [73]
  74. [74]
  75. [75]
  76. [76]
  77. [77]
  78. [78]
  79. [79]
    [PDF] Clinical importance of Staphylococcus pseudintermedius
    Dec 2, 2021 · S. pseudintermedius is a significant pathogen in canines, an agent of infections in humans, and is the focus of this “Pearl”.
  80. [80]
    Staphylococcus pseudintermedius: an undocumented, emerging ...
    Dec 2, 2020 · MRSP can contaminate, colonize or infect animals. Reviews have showed increased resistance in MRSP isolates [17], [91]. Resistance to other ...
  81. [81]
    Carriage of Methicillin‐Resistant Staphylococcus pseudintermedius ...
    Jan 31, 2011 · The rapid spread of MRSP ST71 is of particular concern as this clone tends to be resistant to all antimicrobial agents that are routinely used ...
  82. [82]
    [PDF] Staphylococcus pseudintermedius (MRSP)
    Risk factors in dogs for MRSP carriage include frequent veterinary visits, ... Case–control risk factor study of methicillin-resistant Staphylococcus.
  83. [83]
    [PDF] What Are MRSP & Staphylococcus pseudintermedius?
    Indirect transmission, which occurs when a person or animal gets MRSP from touching an object or surface that has been contaminated with MRSP by another ...<|control11|><|separator|>
  84. [84]
    Staphylococcus pseudintermedius: Is it a real threat to human health?
    ... Staphylococcus aureus is thought to present the greatest risk to humans. ... Studies show that certain conditions, such as atopic dermatitis in dogs, promote more ...
  85. [85]
    [PDF] What is Methicillin- resistant Staphylococcus Pseudintermedius?
    Owners of infected pets and veterinarians in contact with infected animals have a slightly higher risk of acquiring MRSP. There are, however, very low numbers ...<|separator|>
  86. [86]
    [PDF] Recommendations for approaches to meticillin-resistant ...
    It was isolated from pigeons, dogs, mink and horses, and the species name derived from the investigator's observation that the biochemical characteristics of ...
  87. [87]
    Effect of topical antimicrobial therapy and household cleaning on ...
    Sep 27, 2021 · Staphylococcus pseudintermedius, irrespective of its drug resistance, belongs to the normal canine microbiota and colonises the skin and ...
  88. [88]
    Prevalence of methicillin-resistant Staphylococcus ... - NIH
    Prevalence of MRSP in healthy companion animal populations has been reported to range from 0% to 4%, whereas prevalence of MRSP in dogs presented to a ...
  89. [89]
    Methicillin-Resistant Staphylococcal Infections - WSAVA2010 - VIN
    Changes to standard susceptibility testing guidelines for S. pseudintermedius were released in 2010, and will hopefully improve accuracy of diagnosis, provided ...
  90. [90]
    A One Health framework for global and local stewardship across the ...
    Oct 7, 2025 · Antimicrobial resistance (AMR) is a One Health challenge, affecting human and animal health, plants and the environment.
  91. [91]
    [PDF] 2025-2029 | National ONE HEALTH Framework to Address Zoonotic ...
    The NOHF-Zoonoses presents goals and objectives for application of the One Health approach to protect people, animals, and our shared environment in the U.S. ...